DRW Securities’s Adaptive Biotechnologies ADPT Stock Holding History

DRW Securities’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-33,863	Closed	-$470K	–	936
2026 Q1	$470K	Buy	+33,863	New	+$540K	0.01%	639

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

DRW Securities's ADPT Position: Q2 2026 in Review

DRW Securities sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 33,863 shares — an estimated $470K sold.

DRW Securities first reported a position in ADPT in Q1 2026 and held it in 1 quarter. The position peaked at $470K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

DRW Securities reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 33,863 Adaptive Biotechnologies shares in Q2 2026, an estimated $470K.
DRW Securities first reported a position in Adaptive Biotechnologies in Q1 2026 and held it in 1 quarter.
DRW Securities's Adaptive Biotechnologies position peaked at $470K in Q1 2026.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.